Male, 60 years old, Tibetan ethnicity. Primary hepatocellular carcinoma, two weeks after transhepatic artery embolization, was treated with CT-guided percutaneous percutaneous liver cancer radiofrequency ablation under general anesthesia at the People’s Hospital of Tibet Autonomous Region on September 1, 2012, and was discharged 3 days after surgery (see below). Summary: Hepatocellular carcinoma is a common clinical tumor. 70% of the patients are already in the middle and late stage when they are found and have no chance of surgical treatment; moreover, even for patients who have undergone surgical resection of hepatocellular carcinoma, the recurrence rate after 5 years is about 50%. For these patients, interventional treatments such as transhepatic artery embolization therapy (TACE) and radiofrequency ablation therapy have the advantages of being minimally invasive, safe, and can be used for multiple treatments, which can effectively control the tumor and prolong the life of patients. Some studies have shown that for small hepatocellular carcinoma with diameter less than 3CM, the 5-year survival rate after radiofrequency ablation treatment can be comparable to that of surgery. As the medical level in Tibet is relatively backward, our medical team from the Academy of Medical Sciences carried out this treatment technology for the first time in the People’s Hospital of the autonomous region this year and completed 4 cases of radiofrequency ablation treatment, all of which were successful.